Pharmaceuticals

GSK's Arexvy Vaccine Approved in Japan for Adults Aged 18-49

GSK Initiates Final £180 Million Stock Repurchase

GSK and SBP Group enter exclusive cooperation to accelerate Bepirovirsen commercialization in China

Chongqing Tianqing and GSK Reach Commercial Cooperation on Hepatitis B Drug Bepirovirsen in Mainland China

GSK plans to showcase Exdensur's research for type 2 respiratory diseases

GSK's Linerixibat Approved by UK for Pruritus in Primary Biliary Cholangitis

GSK released FY2026 Q1 earnings on April 29 Pre-Market (EST), actual revenue USD 10.06 B (forecast USD 10.04 B), actual EPS USD 1.1233 (forecast USD 0.8971)

GSK CEO to Provide Update on R&D Plans in Q2

GSK Reports Q1 Earnings and Reaffirms Guidance

Deutsche Bank Analyst Reiterates Hold Rating on GSK

GSK's Bepirovirsen Filing Accepted by FDA

GSK's Aifors Receives FDA Breakthrough Therapy Designation and EMA PRIME Qualification

Cipla Receives FDA Final Approval for Generic Ventolin HFA

GSK Expands Stock Repurchase Program

GSK to Release FY2026 Q1 Earnings on April 29 Pre-Market EST, Forecast Revenue USD 10.29 B, EPS USD 0.8971

GSK's Belantamab mafodotin Approved for Market in China

GSK repurchased 330,000 shares

GSK Completes Acquisition of 35PHARMA

Positive Clinical Trial Results for GSK's Ovarian Cancer Drug Mocertatug Rezetecan

FDA Revokes GlaxoSmithKline's Wellcovorin Approval

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

BATS

FENI

The Fidelity Enhanced International ETF (FENI) has seen a notable inflow of approximately $311.7 million, marking a 3.4% increase in outstanding units week-over-week. Key components include British American Tobacco (BTI) down 1%, AerCap Holdings (AER) down 1.6%, and GSK (GSK) up 1.1%. FENI's 52-week range is $31.80 to $40.90, with the last trade at $39.09.

nasdaq

British American Tobacco

British American Tobacco p.l.c.

GlaxoSmithKline plc

Aercap Holdings NV

Fidelity Enhanced International ETF

Nasdaq

General Motors

GSK plc Sponsored ADR

Notable ETF Inflow Detected - FENI, BTI, AER, GSK

RYAAY

European stock markets rose on Monday, with the Stoxx Europe up 0.4% and Germany's DAX gaining 1.3%, amid rising oil prices and interest rates. In corporate news, Novartis reported positive results for its Pluvicto cancer medication, while AstraZeneca and Roche announced a partnership in digital pathology. UBS faced senior banker departures, and Ryanair warned of challenges due to high fuel prices. GSK's RSV vaccine received expanded approval in Japan.

Fidelity

Ryanair

NOVARTIS AG

AstraZeneca PLC

AstraZeneca

UBS Group AG

Novartis AG

Ryanair Holdings Plc

European Stocks Trend Higher in Monday Trading Despite Specter of Middle East War Reigniting

GSK plc announced that Japan's Ministry of Health, Labour and Welfare has expanded the eligible population for its RSV vaccine, Arexvy, to include adults aged 18 to 49 at increased risk for RSV disease. This follows previous approvals for older adults. The decision was supported by Phase IIIb trial data showing a comparable immune response in the younger age group. GSK shares closed at 1,859.50 pence, down 0.16%.

rttnews

Agenus

AGENUS INC

GSK: Japan's MHLW Expands Eligible Population For Arexvy

GSK plc insider Julie Brown purchased 7 shares of the company's stock on May 12th for a total of £130.62 at an average price of GBX 1,866 per share. This follows her earlier acquisition of 5 shares at GBX 2,171 each on April 13th. GSK's current stock price is GBX 1,872.50, with a market cap of £74.75 billion and a P/E ratio of 13.18.

Market Beat

Akebia Therap

Jefferies Financial

Deutsche Bank AG

Citigroup

Yeti

Cisco

Amazon

Alibaba

BABA-W

Deutsche Bank AG Subscription Rights

Deutsche Postbank AG

CITIGROUP INC 6.250 NON CUM SER II PFD WI

BABA-WR

Alibaba HK SDR 5to1

GSK (LON:GSK) Insider Purchases £130.62 in Stock

01177

GSK has partnered with SBP Group to launch bepirovirsen in China, leveraging CTTQ's extensive network of over 5,000 medical centers. GSK will manage regulatory and quality oversight while SBP Group handles distribution and promotional activities. Bepirovirsen, an investigational treatment for chronic hepatitis B, aims to address a significant healthcare issue affecting 75 million people in China. The drug has received priority review and breakthrough designations in multiple countries. GSK's recent acquisition of SiranBio's therapy further supports its expansion into new treatment areas.

Pharmaceutical Business Review

SBP GROUP

Ionis Pharma

GSK and SBP Group team up to advance bepirovirsen launch in China

GSK has entered an exclusive collaboration with Sino Biopharmaceutical (SBP Group) through its subsidiary Chia Tai Tianqing Pharmaceutical Group (CTTQ) to advance the launch of Bepirovirsen in mainland China. CTTQ will manage importation, distribution, and promotional activities across over 5,000 medical centers, while GSK retains marketing authorization and regulatory responsibilities. Bepirovirsen is a triple-action antisense oligonucleotide aimed at treating chronic hepatitis B, with the potential to significantly improve cure rates. The FDA has accepted a New Drug Application for Bepirovirsen, granting it Priority Review and Breakthrough Therapy Designation.

Pharmexec

<![CDATA[GSK Enters Exclusive Collaboration with SBP Group to Accelerate Bepirovirsen at Launch in Mainland China ]]>

G Sachs has raised the target price for SBP GROUPto HKD8.05, maintaining a Buy rating following the company's agreement with GlaxoSmithKline (GSK) for exclusive commercialization rights in China for the hepatitis B drug bepirovirsen. The drug, expected to be approved in 2027, aligns with the treatment needs of China's 75 million chronic hepatitis B patients. G Sachs has increased its earnings forecasts for 2027 and 2028 by 1.1% and 1.7%, respectively, reflecting the anticipated sales contribution from bepirovirsen.

AASTOCKS News

E Fund CSI 300 Health Care ETF

ChinaAMC SSE Health Care ETF Initiating Fund

E Fund CSI Biotechnology Theme ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Guotai SSE STAR Brand Name Drug ETF

ChinaAMC CSI Biotechnology Theme ETF

ChinaAMC SSE STAR Biology and Medicine ETF

China Merchants CSI Biotechnology Theme ETF

Huaan Hang Seng Biotech ETF

Penghua SSE STAR Biology and Medicine ETF

Guotai CSI Bio-medicine ETF

ICBCCS SSE STAR Biology and Medicine ETF

Yinhua CSI Innovative Drugs Industry ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Minsheng Royal CSI Biotechnology Theme ETF

Tianhong CNI BIOMEDICINE ETF

China Universal 800 Health Care ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

E Fund Hang Seng SCHK Innovative Drug ETF

China Southern Hang Seng Biotech ETF(QDII)

GF CSI HK Innovative Drugs Industry ETF(QDII)

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Goldman Sachs

GS Hldg R

G Sachs Raises SBP GROUP  TP to HKD8.05, Maintains Buy on Introduction of GSK Hepatitis B Drug

GSK has partnered with Sino Biopharmaceutical to launch bepirovirsen, a potential hepatitis B treatment in China, targeting a significant patient population. This collaboration enhances GSK's infectious disease pipeline in a major healthcare market. However, investors should monitor regulatory progress, development pace, and the impact on GSK's valuation, which is currently 59.1% below fair value, with a recent share price decline of 15.2%. Concerns about dividend stability and debt levels may also affect investment decisions.

Simplywall

GSK China Hepatitis B Push Raises Questions For Valuation And Dividend Risks

GSK(GSK.US)